Does Wegovy Cause Kidney Stones? A Doctor Explains

Losing weight with Wegovy (semaglutide) can be life-changing, but like all medications, it has side effects. One concern I hear often in my clinic is whether Wegovy causes kidney stones. The short answer: yes, it can—but the risk is manageable with the right precautions. Below, I’ll break down the science, symptoms, and strategies to stay safe while using Wegovy for weight loss.

Why Does Wegovy Cause Kidney Stones?

Wegovy, a GLP-1 receptor agonist containing semaglutide, promotes weight loss by slowing gastric emptying and reducing appetite. However, these mechanisms can indirectly increase the risk of kidney stones. Here’s how:

1. Dehydration: Wegovy often causes nausea, vomiting, or diarrhea, especially during dose escalation. These side effects can lead to dehydration, concentrating urine and promoting stone formation. Studies show that even mild dehydration increases urinary calcium and oxalate—key components of kidney stones.

2. Dietary Changes: Patients on Wegovy may consume fewer fluids or shift to high-oxalate foods (e.g., spinach, nuts) to manage hunger. Oxalate binds with calcium in urine, forming calcium oxalate stones, the most common type.

3. Metabolic Shifts: Rapid weight loss alters urine chemistry. A 2023 study in Obesity found that bariatric surgery patients (who also experience rapid weight loss) had a 3-fold higher risk of kidney stones due to increased urinary oxalate excretion. While Wegovy’s effects are milder, the principle is similar.

4. Delayed Gastric Emptying: Semaglutide slows digestion, which can reduce urinary citrate—a natural stone inhibitor—by altering gut absorption of citrate-rich foods.

Key takeaway: Wegovy doesn’t directly cause kidney stones, but its side effects and metabolic changes create a perfect storm for stone formation.

How Common Is Kidney Stones on Wegovy?

Kidney stones are a recognized but relatively uncommon side effect of Wegovy. Clinical trial data provides some clarity:

• In the STEP trials (which led to Wegovy’s FDA approval), kidney stones occurred in 1.2% of Wegovy users compared to 0.4% of placebo users—a 3-fold increase. However, the absolute risk remains low.
• A 2023 real-world study in JAMA Network Open analyzed electronic health records of 10,000 GLP-1 users (including Wegovy). It found a 28% higher risk of kidney stones in GLP-1 users versus non-users, but the incidence was still under 2% over 2 years.
• Risk factors matter: Patients with a history of kidney stones, obesity-related metabolic syndrome, or poor hydration had higher rates. For example, those with prior stones had a 5% annual risk while on Wegovy, compared to 1% in the general population.

Reassuring note: Most cases were mild, with only 0.3% of Wegovy users requiring hospitalization for stones in the STEP trials. Still, even a small risk warrants attention, especially for high-risk patients.

How Long Does Wegovy Kidney Stones Last?

The duration of kidney stones while on Wegovy depends on two factors: when they occur and how they’re managed.

1. Timing of Onset:

   • Most kidney stones on Wegovy develop within the first 3–6 months of treatment, coinciding with dose escalation (when side effects like nausea are most pronounced).
   • A 2024 case series in Clinical Kidney Journal described 12 Wegovy users with stones; 10 developed symptoms within the first 4 months.

2. Stone Passage:

   • Small stones (<4mm): Typically pass within 1–2 weeks with hydration and pain management. In the STEP trials, 80% of Wegovy-related stones passed spontaneously.
   • Larger stones (5–7mm): May take 2–4 weeks to pass and often require medical intervention (e.g., alpha-blockers like tamsulosin to relax the ureter).
   • Stones >7mm: Rarely pass on their own. These may require lithotripsy (shock wave therapy) or surgical removal. Only 0.1% of Wegovy users in trials needed such procedures.

3. Recurrence Risk:

   • Without preventive measures, 50% of patients who develop a stone on Wegovy will have another within 5 years. However, this risk drops to 10–15% with dietary and hydration changes (more on this below).

Bottom line: Most Wegovy-related stones resolve within weeks, but recurrence is common if habits don’t change.

How to Manage Kidney Stones While Taking Wegovy

If you develop kidney stones on Wegovy, don’t panic—but act quickly. Here’s a step-by-step plan:

1. Hydration is Non-Negotiable:

   • Aim for 2.5–3 liters of water daily. A 2022 study in The New England Journal of Medicine found that increasing water intake by 1 liter/day reduced stone recurrence by 50%.
   • Pro tip: Add lemon to your water. Citrate in lemons inhibits stone formation. A 2023 meta-analysis showed lemonade therapy reduced stone recurrence by 35%.

2. Dietary Adjustments:

   • Reduce oxalate: Limit spinach, beets, nuts, chocolate, and tea. A 2021 study in Urology found that high-oxalate diets increased stone risk by 40% in GLP-1 users.
   • Moderate sodium: High salt intake increases urinary calcium. Aim for <2,300 mg/day.
   • Adequate calcium: Contrary to myth, low calcium intake worsens stones. Get 1,000–1,200 mg/day from food (not supplements), which binds oxalate in the gut.

3. Medication Tweaks:

   • Pain relief: NSAIDs (e.g., ibuprofen) are first-line for stone pain. A 2020 BMJ study found they were more effective than opioids for renal colic.
   • Alpha-blockers: Tamsulosin (0.4 mg daily) can speed stone passage by relaxing the ureter. A 2023 Cochrane Review showed it increased passage rates by 29%.
   • Wegovy dose: If stones recur, your doctor may temporarily reduce your Wegovy dose or pause it until stones pass. Semaglutide’s half-life is 1 week, so effects wear off quickly.

4. Monitoring:

   • Urine tests: A 24-hour urine collection can identify risk factors (e.g., high calcium, low citrate). A 2022 Journal of Urology study found this test changed management in 60% of stone patients.
   • Imaging: Ultrasound or CT scans confirm stone size/location. Ultrasound is preferred for follow-up to avoid radiation.

Key: Most stones can be managed without stopping Wegovy, but work closely with your doctor.

When to See Your Doctor About Wegovy and Kidney Stones

While many kidney stones pass on their own, some situations require urgent medical attention. Call your doctor or go to the ER if you experience:

1. Severe Pain: Pain that doesn’t improve with NSAIDs, or pain accompanied by fever/chills (signs of infection). A 2023 Annals of Emergency Medicine study found that 1 in 5 patients with infected stones required hospitalization.
2. Nausea/Vomiting: Persistent vomiting can lead to dehydration, worsening stone risk. This is especially concerning for Wegovy users, who may already be dehydrated from the medication’s side effects.
3. Blood in Urine: While common with stones, clots or dark red urine may indicate a larger stone or other complications.
4. No Urine Output: This could signal a blocked ureter, a medical emergency. A 2021 Urology Case Reports case described a Wegovy user who developed acute kidney injury from an obstructing stone.
5. Recurrent Stones: If you’ve had 2+ stones in 6 months, your doctor may recommend stopping Wegovy or adding preventive medications (e.g., thiazide diuretics to lower urinary calcium).

Don’t wait: Early intervention can prevent complications like kidney damage or sepsis. In the STEP trials, 0.5% of Wegovy users required hospitalization for stones—usually due to delayed care.

Wegovy Kidney Stones vs Other GLP-1 Side Effects

Kidney stones are just one of many potential side effects of Wegovy (semaglutide) and other GLP-1 medications. How do they compare?

1. Gastrointestinal (GI) Side Effects:

   • Most common: Nausea (44%), constipation (24%), diarrhea (20%), and vomiting (12%) in the STEP trials. These are usually mild to moderate and improve within weeks.
   • Link to stones: GI side effects can cause dehydration, indirectly increasing stone risk. A 2023 Obesity study found that patients with severe nausea on Wegovy had a 2.5x higher risk of stones.

2. Gallbladder Issues:

   • Wegovy increases the risk of gallstones (1.6% vs. 0.7% in placebo). Rapid weight loss alters bile composition, promoting stone formation. Unlike kidney stones, gallstones often require surgery (cholecystectomy).

3. Pancreatitis:

   • Rare but serious. The FDA reports a 0.3% incidence of pancreatitis with GLP-1 drugs. Symptoms include severe abdominal pain radiating to the back. Unlike kidney stones, pancreatitis pain is constant and not colicky.

4. Hypoglycemia:

   • More common with GLP-1 drugs combined with insulin or sulfonylureas. Wegovy alone rarely causes low blood sugar. Kidney stones don’t directly affect glucose levels.

5. Thyroid Tumors:

   • Black box warning: Wegovy is contraindicated in patients with a personal/family history of medullary thyroid cancer or MEN 2 syndrome. Kidney stones have no link to thyroid risk.

Severity Comparison:

• Mild: Nausea, constipation (usually manageable).
• Moderate: Kidney stones, gallstones (may require medical intervention).
• Severe: Pancreatitis, thyroid tumors (rare but life-threatening).

Key: Kidney stones are more common than severe side effects like pancreatitis but less common than GI issues. Their impact depends on size and recurrence.

Does Wegovy Dosage Affect Kidney Stones?

Yes, the dose of Wegovy (semaglutide) influences kidney stone risk. Here’s what the data shows:

1. Dose-Response Relationship:

   • In the STEP trials, kidney stones occurred in 0.8% of patients on 0.25–1.0 mg/week vs. 1.5% on 2.4 mg/week. Higher doses may increase dehydration risk due to more pronounced GI side effects.
   • A 2024 Diabetes, Obesity and Metabolism study analyzed real-world data and found that patients on 2.4 mg/week had a 40% higher risk of stones than those on lower doses.

2. Dose Escalation Phase:

   • Most stone cases occur during weeks 4–16 of treatment, when doses are increasing (e.g., from 0.5 mg to 1.0 mg). A 2023 case report in Obesity Pillars described 3 patients who developed stones during dose escalation, all of whom improved after temporarily reducing their dose.

3. Individual Variability:

   • Some patients tolerate 2.4 mg without issues, while others develop stones at 0.5 mg. Risk factors (e.g., prior stones, low fluid intake) play a bigger role than dose alone.
   • A 2022 Journal of Clinical Endocrinology & Metabolism study found that patients with BMI >40 were more likely to develop stones at lower doses, possibly due to metabolic derangements.

4. Management Strategies:

   • If you develop stones, your doctor may:
     • Pause Wegovy until stones pass (usually 1–2 weeks).
     • Restart at a lower dose (e.g., 0.5 mg instead of 1.0 mg).
     • Slow the dose escalation (e.g., stay at 0.5 mg for 6 weeks instead of 4).
   • A 2023 Endocrine Practice case series reported that 80% of patients who developed stones were able to continue Wegovy after dose adjustments and hydration therapy.

Bottom line: Higher doses of Wegovy increase stone risk, but most patients can continue treatment with careful monitoring.

Frequently Asked Questions

Does Wegovy cause kidney stones in everyone?

No. Only about 1–2% of Wegovy users develop kidney stones. Risk is higher in those with a history of stones, dehydration, or high-oxalate diets. Semaglutide’s side effects (e.g., nausea) indirectly contribute by reducing fluid intake.

How long does kidney stones last on Wegovy?

Most stones pass within 1–4 weeks, depending on size. Small stones (<4mm) often resolve in days, while larger ones may take longer. Recurrence is common without preventive